NOV Latest Quotes, Charts & Stock Information

Home » NOV

Latest Insights on NOV

Wall Street's vaccine rally was a nice diversion, but it’s time to face facts. We still have a long walk down that road to recovery.

Retail’s Reality, Tesla’s 500 and Bezos’ Benzos November 17, 2020 by Joseph Hargett Great Stuff Back to Life, Back to Reality I’m rolling with a little late ‘80s hip-pop today. I know that’s not everyone’s cup of tea, but this ‘89 Soul II Soul classic seemed rather appropriate given this morning’s October retail sales data: Back to life, back to the present time, back from a fantasy. The vaccine rally […]

How Activist Investors Saved Papa John’s Stock November 17, 2020 by Chad Shoop American Investor Today, Education, Investing (4-minute read) The collapse of Papa John’s is old news. Mostly because it’s recovered since its founder spiraled out of control. But that recovery is a story in itself…

Can you be too cool for the vaccine race? As it turns out, yes you can! With Moderna’s vaccine coming in hot, Pfizer just got one-upped.

Pfizer Pforfeit; A Nio Dealio; Uber’s Hail Mary November 16, 2020 by Joseph Hargett Great Stuff Born to Run In the day, we sweat it out on Wall Street. It’s a runaway American dream. At night, we’re locked in mansions of glory, no more suicide machines. But all that might be about to change… Sprung from Phase 3 on highway nine, Moderna’s new injection is stepping out over the line. (Woah!) […]

Wall Street’s No. 1 Mistake: Ignoring Long-Term Profits November 16, 2020 by Charles Mizrahi American Investor Today, Education, Investing (4-minute read) A vaccine is on the horizon. Wall Street “experts” are scrambling to take advantage. But they’re focusing on the wrong thing...

The effectiveness of the COVID-19 vaccine is remarkable. But what’s even more remarkable is that a relatively small firm played such a large role in developing it.

COVID-19 Vaccine Firm Soars 650% — Huge Opportunities Ahead November 14, 2020 by Jay Goldberg Investment Opportunities, Winning Investor Daily The effectiveness of the COVID-19 vaccine is remarkable. But what’s even more remarkable is that a relatively small firm played such a large role in developing it.